MIRA Pharmaceuticals Completes SKNY Acquisition

MIRA Pharmaceuticals, Inc. ( (MIRA) ) has issued an announcement.

On September 29, 2025, MIRA Pharmaceuticals completed its acquisition of SKNY Pharmaceuticals, enhancing its financial position and expanding its drug development pipeline. This strategic move positions MIRA as a multi-program developer with potential treatments for significant unmet medical needs. Additionally, the company addressed a compliance issue with Nasdaq’s listing requirements, regaining compliance through stock sales and the merger, although it remains under monitoring for ongoing compliance.

The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing a pipeline of drug candidates targeting high-value therapeutic areas. Its primary products include Ketamir-2, MIRA-55, and SKNY-1, which address neuropathic pain, inflammatory pain, cognitive decline, anxiety, obesity, and smoking cessation.

Average Trading Volume: 1,523,674

Technical Sentiment Signal: Sell

See more data about MIRA stock on TipRanks’ Stock Analysis page.